menu

Overcoming Clinical Inertia in Hyperkalemia Management

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Overcoming Clinical Inertia in Hyperkalemia Management

0.25 credits
15 minutes
ReachMD Healthcare Image
Restart
Resume
Choose a format
Take Post-TestSkip straight to the post-test if you have already participated in this activity
Media formats available:
0.25 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
Comments
  • Overview

    This activity addresses the challenges of managing hyperkalemia in patients with chronic kidney disease (CKD) with co-existing conditions. Find out how CKD, heart failure, and hyperkalemia impact adherence to renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, a critical approach for these patients. Our experts also have insights on the importance of interdisciplinary collaboration among healthcare professionals in managing complex cases like hyperkalemia in patients with CKD.

  • Disclosures of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Peter Rossing, DMSc, MD
    Professor, Diabetic Angiopathy
    University of Copenhagen
    Copenhagen, Denmark

    Dr. Rossing has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Novo Nordisk, Sanofi
    Contracted Research: AstraZeneca, Bayer, Novo Nordisk

    Faculty:
    Michael Böhm, MD, FESC
    Director, Clinic for Internal Medicine III
    Saarland University Hospital
    Homburg/Saar, Germany

    No relevant relationships reported

    Luca De Nicola, MD, PhD
    Professor of Nephrology
    Director, Nephrology-Dialysis Unit and Postgraduate School of Nephrology
    Department of Advanced Medical and Surgical Sciences
    University of Campania “Luigi Vanvitelli”
    Naples, Italy

    Dr. De Nicola has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas, AstraZeneca, Bayer, Novo Nordisk

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard J. Green, MS, MBA, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the impact of coexisting chronic kidney disease (CKD) with its comorbidities (eg, diabetes, heart failure) and hyperkalemia on renin-angiotensin-aldosterone system inhibitor (RAASi) adherence
    • Develop optimal treatment sequences and strategies to overcome clinical inertia while treating hyperkalemia while maintaining RAASi therapy in patients with CKD
    • Recognize the importance of an interdisciplinary collaboration between healthcare professionals when managing a complex condition like hyperkalemia
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, endocrinologists, primary care physicians, cardiologists, and all HCPs involved in the identification and treatment of hyperkalemia in CKD patients.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    This activity addresses the challenges of managing hyperkalemia in patients with chronic kidney disease (CKD) with co-existing conditions. Find out how CKD, heart failure, and hyperkalemia impact adherence to renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, a critical approach for these patients. Our experts also have insights on the importance of interdisciplinary collaboration among healthcare professionals in managing complex cases like hyperkalemia in patients with CKD.

  • Disclosures of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Host:
    Peter Rossing, DMSc, MD
    Professor, Diabetic Angiopathy
    University of Copenhagen
    Copenhagen, Denmark

    Dr. Rossing has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Gilead, Merck, Mundipharma, Novo Nordisk, Sanofi
    Contracted Research: AstraZeneca, Bayer, Novo Nordisk

    Faculty:
    Michael Böhm, MD, FESC
    Director, Clinic for Internal Medicine III
    Saarland University Hospital
    Homburg/Saar, Germany

    No relevant relationships reported

    Luca De Nicola, MD, PhD
    Professor of Nephrology
    Director, Nephrology-Dialysis Unit and Postgraduate School of Nephrology
    Department of Advanced Medical and Surgical Sciences
    University of Campania “Luigi Vanvitelli”
    Naples, Italy

    Dr. De Nicola has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:
    Consulting Fees: Astellas, AstraZeneca, Bayer, Novo Nordisk

    Reviewers/Content Planners/Authors:

    • Cindy Davidson has nothing to disclose.
    • Ann Early has nothing to disclose.
    • Howard J. Green, MS, MBA, has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Tim Person has nothing to disclose.
    • Mario Trucillo, PhD, MS, has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Evaluate the impact of coexisting chronic kidney disease (CKD) with its comorbidities (eg, diabetes, heart failure) and hyperkalemia on renin-angiotensin-aldosterone system inhibitor (RAASi) adherence
    • Develop optimal treatment sequences and strategies to overcome clinical inertia while treating hyperkalemia while maintaining RAASi therapy in patients with CKD
    • Recognize the importance of an interdisciplinary collaboration between healthcare professionals when managing a complex condition like hyperkalemia
  • Target Audience

    This activity is designed to meet the educational needs of nephrologists, endocrinologists, primary care physicians, cardiologists, and all HCPs involved in the identification and treatment of hyperkalemia in CKD patients.

  • Accreditation and Credit Designation Statements

    In support of improving patient care, Global Learning Collaborative (GLC) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    The American Medical Association has an agreement of mutual recognition of Continuing Medical Education (CME) credits with the European Union of Medical Specialists (UEMS), the accreditation body for European countries. Physicians interested in converting AMA PRA Category 1 CreditsTM to UEMS-European Accreditation Council for Continuing Medical Education CME credits (ECMECs) should contact the UEMS at mutualrecognition@uems.eu.

    Global Learning Collaborative (GLC) designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 0.25 nursing contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant from CSL Vifor.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule30 May 2024